An Osaka University-led research team has recently published findings that provide a ray of hope for the millions of Parkinson’s disease (PD) sufferers worldwide. Although more common in those aged over sixty, PD can strike at any age, with an estimated prevalence of 41 per 100,000 people in their forties. And while not fatal in and of itself, the progressive neurodegeneration that is characteristic of PD can often cause secondary effects that lead to death.
The exact cause of PD is still a mystery, but researchers believe that both genetics and the environment are likely to play a part. Importantly though, all PD patients show a loss of dopaminergic neurons in the brain and increased levels of a protein called ?-synuclein, which accumulates in Lewy bodies. Lewy bodies are a pathological feature of both familial and sporadic forms of the disease, as well as some types of dementia.
In the study published this month in Scientific Reports, the team led by researchers from Osaka University’s Graduate School of Medicine focused on ?-synuclein as a target for a novel PD treatment.
“Although there are drugs that treat the symptoms associated with PD, there is no fundamental treatment to control the onset and progression of the disease,” explains lead author Takuya Uehara. “Therefore, we looked at ways to prevent the expression of ?-synuclein and effectively eliminate the physiological cause of PD.”
To do this, the researchers designed short fragments of DNA that are mirror images of sections of the ?-synuclein gene product. The constructs were stabilized by the addition of amido-bridging. The resulting fragments, called amido-bridged nucleic acid-modified antisense oligonucleotides (ASOs), bind to their matching mRNA sequence, preventing it from being translated into protein. After screening 50 different ASOs, the researchers settled on a 15-nucleotide sequence that decreased ?-synuclein mRNA levels by 81%.
“When we tested the ASO in a mouse model of PD, we found that it was delivered to the brain without the need for chemical carriers,” says co-lead author Chi-Jing Choong. “Further testing showed that the ASO effectively decreased ?-synuclein production in the mice and significantly reduced the severity of disease symptoms within 27 days of administration.”
Explains senior author of the study Hideki Mochizuki, “Our results showed that gene therapy using ?-synuclein-targeting ASOs is a promising strategy for the control and prevention of PD. We expect that in the future, this method will be used to not only successfully treat PD, but also dementia caused by ?-synuclein accumulation.”
Learn more: Stopping Parkinson’s disease before it starts
The Latest on: Parkinson’s disease
via Google News
The Latest on: Parkinson’s disease
- FUJIFILM Cellular Dynamics Launches Parkinson’s Disease iCell DopaNeurons featuring LRRK2 and GBA Mutationson May 24, 2022 at 6:03 am
FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cell (iPSC) products, announced today the launch of Parkinson’s disease (PD) iCell ...
- Spotting Parkinson's disease earlier through AI: U.S. inventor Erin Smith named Young Inventors prize 2022 finaliston May 24, 2022 at 5:24 am
Erin Smith (22) named as one of three finalists of a new prize awarded by the European Patent Office (EPO) for her AI-powered tool enabling early ...
- AbbVie (ABBV) Files NDA for Parkinson's Disease Candidateon May 23, 2022 at 8:46 am
AbbVie (ABBV) submits a new drug application to the FDA for ABBV-951, which has been developed for treating advanced Parkinson's disease.
- Parkinson’s disease: Cerevance outlines Phase II/III trial planned for Q1 2023on May 23, 2022 at 8:35 am
Cerevance CMO Jordan Dubow shares exclusive details on the first of two planned registrational trials in Parkinson’s disease.
- Journal of Parkinson’s Disease welcomes new co-Editor-in-Chief Lorraine V. Kalia, MD, PhD, FRCPCon May 20, 2022 at 1:18 pm
The Journal of Parkinson’s Disease (JPD), published by IOS Press, is pleased to announce the appointment of new co-Editor-in-Chief, Lorraine V. Kalia, MD, PhD, FRCPC. Dr. Kalia joins ...
- Study in mice suggests that COVID-19 increases risk of developing Parkinson's diseaseon May 18, 2022 at 12:54 pm
Brain fog, headaches, and insomnia are some of the neurological symptoms doctors have observed in COVID-19 patients. Neurological sequelae after a viral infection is not new—in fact, following the ...
- Do Probiotics Aid Parkinson’s Disease?on May 18, 2022 at 6:46 am
Parkinson’s disease is a progressive neurodegenerative disorder that affects over 1 million people in the United States (1). A neurotransmitter called dopamine is important for your body’s ...
- Global Parkinson’s Disease Drugs Market To Be Driven By Ageing Demographics In The Forecast Period Of 2021-2026on May 18, 2022 at 4:37 am
The new report by Expert Market Research titled, ‘Global Parkinson’s Disease Drugs Market Report and Forecast 2021-2026’, gives an in-depth analysis of ...
- Researchers reveal how the volumes of brain regions change in Parkinson's diseaseon May 17, 2022 at 10:06 am
A team of researchers from Forschungszentrum Jülich, Heinrich-Heine-University Düsseldorf and Ernst-von-Bergmann Klinikum Potsdam analyzed the changes of brain volumes in 37 Parkinson's patients and ...
- Designer neurons bring hope for treatment of Parkinson’s diseaseon May 12, 2022 at 1:23 pm
A futuristic approach to stem cell replacement therapy will soon be put to the test in the first of its kind clinical trial.
via Bing News